^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DLL3 inhibitor

    Related drugs:
    2d
    DeLLphi-313: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=160, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle)
    4d
    20250114: Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer (2025-522888-15-00)
    P1, N=11, Not yet recruiting, Amgen Inc.
    New P1 trial
    |
    Imdelltra (tarlatamab-dlle)
    4d
    MERLIN: Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients (clinicaltrials.gov)
    P2, N=37, Recruiting, Fundación GECP
    Trial initiation date
    |
    Imdelltra (tarlatamab-dlle)
    6d
    Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager. (PubMed, Immunotherapy)
    CRS and ICANS emerge primarily during the first two cycles of treatment, have low to moderate severity and are generally manageable with general supportive measures and specialized immunosuppressive treatment including corticosteroids and monoclonal antibodies like tocilizumab. Tarlatamab appears to be a promising choice for relapsed SCLC, based on the results of the Phase III DeLLphi-304 trial, which demonstrated a clinically and statistically meaningful improvement in overall survival (OS) with its use compared to approved second-line chemotherapy (ChT) options. Having been recently granted FDA approval for use in patients with SCLC who progressed on or after platinum-based ChT, tarlatamab is currently being evaluated in multiple settings of SCLC, including first-line and maintenance treatment.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Imdelltra (tarlatamab-dlle) • Actemra IV (tocilizumab)
    8d
    ALPINE 2: A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, Technische Universität Dresden
    New P2 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    carboplatin • obrixtamig (BI 764532)
    10d
    Safety and Preliminary Activity of BI115 in Advanced SCLC (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P1 trial
    10d
    DAREON-5: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers (clinicaltrials.gov)
    P2, N=204, Recruiting, Boehringer Ingelheim | N=109 --> 204
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    obrixtamig (BI 764532)
    10d
    Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (clinicaltrials.gov)
    P1, N=220, Recruiting, Amgen | N=86 --> 220
    Enrollment change
    |
    Imdelltra (tarlatamab-dlle)
    10d
    DeLLphi-309: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (clinicaltrials.gov)
    P2, N=252, Active, not recruiting, Amgen | N=92 --> 252
    Enrollment change
    |
    Imdelltra (tarlatamab-dlle)
    10d
    START-lung: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (clinicaltrials.gov)
    P2, N=48, Recruiting, ETOP IBCSG Partners Foundation
    Trial initiation date
    |
    Imdelltra (tarlatamab-dlle)
    11d
    20240178: Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312) (2024-520050-38-00)
    P2/3, N=129, Active, not recruiting, Amgen Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle) • Sylvant (siltuximab)
    11d
    DeLLphi-306: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
    P3, N=404, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imdelltra (tarlatamab-dlle)